BidaskClub Upgrades STAAR Surgical (STAA) to “Hold”

Share on StockTwits

STAAR Surgical (NASDAQ:STAA) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Other analysts have also issued reports about the stock. Benchmark restated a “buy” rating and issued a $54.00 price objective (up from $45.00) on shares of STAAR Surgical in a report on Monday, September 24th. Zacks Investment Research upgraded shares of STAAR Surgical from a “hold” rating to a “strong-buy” rating and set a $51.00 price objective on the stock in a report on Thursday, November 8th. TheStreet lowered shares of STAAR Surgical from a “b-” rating to a “c” rating in a report on Friday, December 14th. ValuEngine lowered shares of STAAR Surgical from a “strong-buy” rating to a “buy” rating in a report on Friday, December 21st. Finally, Canaccord Genuity boosted their price objective on shares of STAAR Surgical from $43.00 to $55.00 and gave the company a “buy” rating in a report on Friday, September 14th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $45.25.

Shares of STAA opened at $32.51 on Wednesday. The stock has a market capitalization of $1.30 billion, a P/E ratio of 3,251.00 and a beta of 1.99. STAAR Surgical has a 12-month low of $13.60 and a 12-month high of $54.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.76 and a current ratio of 5.35.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Wednesday, October 31st. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.06. The firm had revenue of $31.77 million for the quarter, compared to analyst estimates of $30.10 million. STAAR Surgical had a net margin of 3.17% and a return on equity of 14.80%. During the same period in the previous year, the firm earned $0.03 EPS. Analysts expect that STAAR Surgical will post 0.09 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Winslow Evans & Crocker Inc. acquired a new position in STAAR Surgical in the 3rd quarter valued at about $142,000. Harvest Fund Management Co. Ltd acquired a new position in STAAR Surgical in the 3rd quarter valued at about $222,000. United Services Automobile Association acquired a new position in STAAR Surgical in the 3rd quarter valued at about $278,000. Xact Kapitalforvaltning AB acquired a new position in STAAR Surgical in the 3rd quarter valued at about $278,000. Finally, Advisors Asset Management Inc. acquired a new position in STAAR Surgical in the 3rd quarter valued at about $302,000. Hedge funds and other institutional investors own 85.80% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Recommended Story: How to Invest in Growth Stocks

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply